/r/nsclc

Year:

RILPL2 as a potential biomarker for predicting enhanced T cell infiltration in non-small cell lung cancer

1 upvotes • montaukwhaler

Mark as read: Add to a list

Inhibition of DDR1 promotes ferroptosis and overcomes gefitinib resistance in non-small cell lung cancer

1 upvotes • montaukwhaler

Mark as read: Add to a list

Amivantamab Plus Lazertinib vs Osimertinib for First-Line EGFR-Mutant Advanced NSCLC With Biomarkers of High-Risk Disease

1 upvotes • montaukwhaler

Mark as read: Add to a list

Patient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic

1 upvotes • montaukwhaler

Mark as read: Add to a list

Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experience

1 upvotes • montaukwhaler

Mark as read: Add to a list

Corneal Transplant Rejection Following Durvalumab Therapy in a Patient With NSCLC: A Case Report

1 upvotes • montaukwhaler

Mark as read: Add to a list

Prognostic potential of integrated morphologic and metabolic parameters of pre-therapeutic [18F]FDG-PET/CT regarding progression-free survival (PFS) and overall survival (OS) in NSCLC-patients

1 upvotes • montaukwhaler

Mark as read: Add to a list

Effect of PD‐1/PD‐L1 immune checkpoint inhibitor in squamous and nonsquamous non‐small cell lung cancer: A systematic review and meta‐analysis

1 upvotes • montaukwhaler

Mark as read: Add to a list

Neoadjuvant targeted therapy versus targeted combined with chemotherapy for resectable EGFR-mutant non–small cell lung cancer: a retrospective controlled real-world study

1 upvotes • montaukwhaler

Mark as read: Add to a list

Risk factors of osimertinib-related cardiotoxicity in non-small cell lung cancer

1 upvotes • montaukwhaler

Mark as read: Add to a list

Title	Upvotes	Author	Mark as read	Favorited	Rating	Add to a list
RILPL2 as a potential biomarker for predicting enhanced T cell infiltration in non-small cell lung cancer	1	montaukwhaler
Inhibition of DDR1 promotes ferroptosis and overcomes gefitinib resistance in non-small cell lung cancer	1	montaukwhaler
Amivantamab Plus Lazertinib vs Osimertinib for First-Line EGFR-Mutant Advanced NSCLC With Biomarkers of High-Risk Disease	1	montaukwhaler
Patient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic	1	montaukwhaler
Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experience	1	montaukwhaler
Corneal Transplant Rejection Following Durvalumab Therapy in a Patient With NSCLC: A Case Report	1	montaukwhaler
Prognostic potential of integrated morphologic and metabolic parameters of pre-therapeutic [18F]FDG-PET/CT regarding progression-free survival (PFS) and overall survival (OS) in NSCLC-patients	1	montaukwhaler
Effect of PD‐1/PD‐L1 immune checkpoint inhibitor in squamous and nonsquamous non‐small cell lung cancer: A systematic review and meta‐analysis	1	montaukwhaler
Neoadjuvant targeted therapy versus targeted combined with chemotherapy for resectable EGFR-mutant non–small cell lung cancer: a retrospective controlled real-world study	1	montaukwhaler
Risk factors of osimertinib-related cardiotoxicity in non-small cell lung cancer	1	montaukwhaler